Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06688422 · ClinicalTrials.gov registry record · NA

Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy

A NA study of Lung Cancer and Non-small Cell Lung Cancer (NSCLC), sponsored by The Cooper Health System.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT06688422: Recruiting NA study of Lung Cancer and Non-small Cell Lung Cancer (NSCLC), sponsored by The Cooper Health System.

NCT06688422 is a NA study of Lung Cancer and Non-small Cell Lung Cancer (NSCLC) that is actively recruiting participants, run by The Cooper Health System. The registered enrollment target is 100 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06688422, a NA study of Lung Cancer and Non-small Cell Lung Cancer (NSCLC), is actively recruiting participants, sponsored by The Cooper Health System.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn if using an incentive spirometer can reduce lung problems in people with advanced lung cancer who are receiving chemotherapy and radiation therapy. The main questions the study aims to answer are: Does using an incentive spirometer lower the chances of developing lung inflammation (pneumonitis)? Does it improve overall survival and quality of life? Participants will: Use an incentive spirometer, a device that helps with deep breathing, 10 times every hour while awake. Continue using the spirometer daily during treatment and for up to three months after treatment. Complete quality of life assessments at the start of the study and at 3, 6, and 12 months. Researchers will compare the results to see if the incentive spirometer helps reduce lung problems and improves participants\' well-being during and after their cancer treatment.

Primary Outcome

Primary Endpoint: To determine the impact of incentive spirometry on the incidence of pneumonitis. Assessment Method: Number of participants diagnosed with pneumonitis, assessed using CT scan and clinical diagnostic criteria

Interventions

  • DEVICE incentive spirometry

Study Locations (1)

New Jersey

  • MD Anderson Cancer Center at Cooper - Camden

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-12-01
Est. Completion 2026-12
Phase NA
The Cooper Health System

39 total trials

What NCT06688422 shows while recruiting

NCT06688422 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (89% lower).

The record links to 5 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which incentive spirometry is the first listed.

NCT06688422 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT06688422 about?

NCT06688422 is a clinical study titled "Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy". The goal of this clinical trial is to learn if using an incentive spirometer can reduce lung problems in people with advanced lung cancer who are receiving chemotherapy and radiation therapy. The main questions the study aims to answer are: Does using an incentive spirometer lower the chances of de...

What is the current status of trial NCT06688422?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2024-12-01. Estimated completion is 2026-12.

What conditions does trial NCT06688422 study?

This clinical trial studies the following conditions: Lung Cancer, Non-small Cell Lung Cancer (NSCLC), Pneumonitis, Radiation-Induced Lung Injury, Immunotherapy-Induced Pneumonitis.

What interventions are being tested in trial NCT06688422?

The interventions under investigation include: incentive spirometry (DEVICE).

Who is sponsoring clinical trial NCT06688422?

This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06688422 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06688422's enrollment target sits among peer trials

100 186th of 409 higher than 212 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06688422, the US trial registry maintained by the National Library of Medicine. NCT06688422 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.